25th Guide to German Biotech Companies 2024
ISBN 978-3-928383-89-9
2024 Jubilee Edition
Content
Editorial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3
The German Biotech Sector 2023 . .
7
Profiles of German Biotech Companies . . . . . . . . 4HF Biotec GmbH . . . . . . . . . . . . . . . . . . . . . . . . . Aeterna Zentaris GmbH . . . . . . . . . . . . . . . . . . . . . Affimed GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . AGC Biologics GmbH . . . . . . . . . . . . . . . . . . . . . . Artcline GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . ASKA Biotech GmbH . . . . . . . . . . . . . . . . . . . . . . AvenCell Europe GmbH. . . . . . . . . . . . . . . . . . . . . AxoLabs GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . BAG Health Care GmbH . . . . . . . . . . . . . . . . . . . . Biaffin GmbH & Co. KG . . . . . . . . . . . . . . . . . . . . . BioCopy GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . BioSpring GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . Biotype GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . BRAIN Biotech AG. . . . . . . . . . . . . . . . . . . . . . . . . Cardior Pharmaceuticals GmbH . . . . . . . . . . . . . . CeGaT GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . CLADE GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . Coriolis Pharma Research GmbH . . . . . . . . . . . . . CureVac AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Eppendorf SE . . . . . . . . . . . . . . . . . . . . . . . . . . . . Eurofins BioPharma Product Testing Munich GmbH FGK Clinical Research GmbH . . . . . . . . . . . . . . . . Formycon AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fraunhofer ITEM . . . . . . . . . . . . . . . . . . . . . . . . . . GALAB Laboratories GmbH . . . . . . . . . . . . . . . . . GENEWIZ Germany GmbH . . . . . . . . . . . . . . . . . . Gen-H Genetic Engineering Heidelberg GmbH . . . Gilson International BV Deutschland . . . . . . . . . . . GKM Gesellschaft für Therapieforschung mbH . . . glyXera GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . Heidelberg Pharma AG . . . . . . . . . . . . . . . . . . . . . HS Diagnomics GmbH . . . . . . . . . . . . . . . . . . . . . IBA Lifesciences GmbH. . . . . . . . . . . . . . . . . . . . . ibidi GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IDT Biologika GmbH . . . . . . . . . . . . . . . . . . . . . . . Immunic AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70 72 74 76 78 80 82 84 86 88
Indivumed GmbH . . . . . . . . . . . . . . . . . . . . . . . . . 90 iOmx Therapeutics AG . . . . . . . . . . . . . . . . . . . . . 92 ITM Isotope Technologies Munich SE . . . . . . . . . . 94 KNAUER Wissenschaftliche Geräte GmbH . . . . . . 96 Kupando GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . 98 KyooBe Tech GmbH . . . . . . . . . . . . . . . . . . . . . . . 100 Lonza Cologne GmbH . . . . . . . . . . . . . . . . . . . . . . 102 metabion international AG . . . . . . . . . . . . . . . . . . . 104 Mettler-Toledo GmbH . . . . . . . . . . . . . . . . . . . . . . 106 Microcoat Biotechnologie GmbH . . . . . . . . . . . . . 108 Microsynth Seqlab GmbH . . . . . . . . . . . . . . . . . . . 110 MLM Medical Labs GmbH. . . . . . . . . . . . . . . . . . . 112 Molzym GmbH & Co. KG . . . . . . . . . . . . . . . . . . . . 114 MorphoSys AG . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 Navigo Proteins GmbH . . . . . . . . . . . . . . . . . . . . . 118 Neovii Biotech GmbH . . . . . . . . . . . . . . . . . . . . . . 120 New England Biolabs GmbH . . . . . . . . . . . . . . . . . 122 Nordmark Pharma GmbH . . . . . . . . . . . . . . . . . . . 124 Nova Biomedical GmbH . . . . . . . . . . . . . . . . . . . . 126 Pantherna Therapeutics GmbH . . . . . . . . . . . . . . . 128 Pharmaplan GmbH . . . . . . . . . . . . . . . . . . . . . . . . 130 Phyton Biotech GmbH. . . . . . . . . . . . . . . . . . . . . . 132 PlasmidFactory GmbH & Co. KG . . . . . . . . . . . . . 134 ProBioGen AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136 Process Sensing Technologies PST GmbH . . . . . . 138 PROGEN Biotechnik GmbH . . . . . . . . . . . . . . . . . 140 ProJect Pharmaceutics GmbH . . . . . . . . . . . . . . . 142 ProtaGene GmbH . . . . . . . . . . . . . . . . . . . . . . . . . 144 Rentschler Biopharma SE . . . . . . . . . . . . . . . . . . . 146 Richter-Helm BioLogics GmbH & Co. KG . . . . . . . 148 RNATICS GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . 150 Roche Diagnostics GmbH . . . . . . . . . . . . . . . . . . . 152 Sanofi-Aventis Deutschland GmbH . . . . . . . . . . . . 154 Sartorius CellGenix GmbH . . . . . . . . . . . . . . . . . . 156 ScheBo® Biotech AG . . . . . . . . . . . . . . . . . . . . . . . 158 SciRhom GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . 160 Secarna Pharmaceuticals GmbH & Co. KG . . . . . 162 SERVA Electrophoresis GmbH . . . . . . . . . . . . . . . 164 SGS Analytics Germany GmbH . . . . . . . . . . . . . . . 166 Sino Biological Europe GmbH . . . . . . . . . . . . . . . . 168 Sirius Fine Chemicals SiChem GmbH . . . . . . . . . . 170 T-CURX GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . 172 Tentamus Pharma & Med Deutschland GmbH . . . 174 Therycell GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
Tosoh Bioscience GmbH . . . . . . . . . . . . . . . . . . . . 178 Valicare GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 Vetter Pharma International GmbH . . . . . . . . . . . . 182 Viscofan BioEngineering . . . . . . . . . . . . . . . . . . . . 184 Vivoryon Therapeutics N.V. . . . . . . . . . . . . . . . . . . 186 WuXi Biologics Germany GmbH . . . . . . . . . . . . . . 188 X-act Cologne Clinical Research GmbH . . . . . . . . 190 XL-Protein GmbH . . . . . . . . . . . . . . . . . . . . . . . . . 192 YMC Europe GmbH . . . . . . . . . . . . . . . . . . . . . . . . 194 Yumab GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196 Zedira GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198
Profiles of Service Providers . . . . . . . . . 201 BIO.NRW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202 BIOCOM Interrelations GmbH . . . . . . . . . . . . . . . . 204 BioM Biotech Cluster Development GmbH . . . . . . 206 Biomindz Standortentwicklungsgesellschaft Mainz mbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208 BIOPRO Baden-Württemberg GmbH . . . . . . . . . . 210 btS e.V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212 Carl Roth GmbH & Co. KG . . . . . . . . . . . . . . . . . . 214 HealthCapital Berlin-Brandenburg . . . . . . . . . . . . 216 HOX Life Science GmbH . . . . . . . . . . . . . . . . . . . . 218 IZB - Fördergesellschaft IZB mbH . . . . . . . . . . . . . 220 Life Science Nord Management GmbH . . . . . . . . . 222 LUMIS International GmbH . . . . . . . . . . . . . . . . . . 224 Meissner Bolte Patentanwälte Rechtsanwälte Partnerschaft mbB . . . . . . . . . . . . . . . . . . . . . . . . 226 restracon GmbH & Co. KG . . . . . . . . . . . . . . . . . . 228 Technologiepark Heidelberg GmbH . . . . . . . . . . . 230 Wuesthoff & Wuesthoff Patentanwälte PartG mbB 232
A fine pen with 5 km writing performance. The body is made from biotechnologically produced biopolymers – fully compostable in the garden. Made in Europe
German Biotech Companies . . . . . . . . . 234
Available for 3 EUR exclusively at the
biospheria.shop/en Advertisements BIOMATEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 BIOCOM |transkript . . . . . . . . . . . . . . . . . . . . . . . . 6 eurobiotechjobs.net . . . . . . . . . . . . . . . . . . . . . . . 16 BIOCOM European Biotechnology Magazine . . . . 200
BIOMATEC® 25 TH GUIDE TO GERMAN BIOTECH COMPANIES 2024
4|5
The German Biotechnology Sector 2023
It is a rare case of a collateral gain: The devastating Corona pandemic has cast the German biotechnology industry into the public and capital market spotlight. The mRNA vaccine developed by BioNTech in Mainz proved to be highly effective and paved the way for broad-based vaccination campaigns around the world – the only way to overcome the epidemic. The pandemic raised awareness of the importance of biotech research, development and production, which boosted investment and led to accelerated growth in the biotech industry.
despite the difficult economic environment, the start-up momentum remained unbroken. This is shown by the results of the Biotechnology Company Survey 2023 conducted by BIOCOM AG, which collected the most important key figures in spring 2023. BIOCOM has been analysing the development of the biotechnology industry in Europe for 37 years. Since 2005, the key figures of German biotechnology companies, which are collected annually, have been made internationally comparable according to the criteria of the Organisation for Economic Cooperation and Development (OECD). It was only in 2020 that data collection was suspended due to COVID-19. The figures and graphs given below refer to those companies defined by the OECD as “dedicated” biotech companies.
In 2022, investment was significantly lower than in the previous year, and with the pandemic subsiding and thus significantly lower demand for the Covid vaccine Comirnaty, industry sales also slumped, but less sharply than expected.
Although most of the industry is active in the healthcare sector, Germany is also working on biotechnological innovations in other fields. In industrial biotechnology, there are promising approaches to effectively counter the challenges of climate change. Alternative proteins, for example, are gaining in importance because they combine several advantages: they make a significant contribution to supplying food to the world’s growing population, reduce the consumption of resources and
By contrast, research and development spending rose to a new record level. Biotech companies invested a total of €3.33 billion of which three billion alone went towards researching new active ingredients, technologies and products or improving existing innovations in the healthcare sector. These figures speak for the strong self-confidence of the industry. Companies were also able to continue acquiring qualified employees; and
Key figures of the biotech sector in Germany 2014
2015
2016
2017
2018
2020
2021
2022
Number of dedicated biotechnology companies
579
593
615
646
679
736
753
776
Number of employees in dedicated companies
17,930
19,010
20,280
21,860
23,540
27,200
30,280
34,390
Turnover of dedicated biotechnology companies
€3.03bn €3.28bn €3.54bn €4.11bn €4.51bn €6.71bn €26.5bn €25.4bn
R&D expenditures of dedicated biotechnology companies
€0.95bn €1.04bn €1.10bn €1.12bn €1.19bn €2.14bn €2.83bn €3.33bn
25 TH GUIDE TO GERMAN BIOTECH COMPANIES 2024
6|7
Compared to 2021, the turnover of the 776 dedicated biotech companies dropped to €25.4 billion in 2022. However, when comparing the two years excluding BioNTech sales, sales increased from €7.5 billion in 2021 to €8.1billion. This represents growth of more than 8% and shows that many German biotech companies have now reached a high level of maturity and have been able to hold their ground even in the difficult economic and geopolitical environment.
put a halt to animal suffering. Also, work is underway to develop microorganisms that can break down carbon dioxide, thereby helping to reduce CO2 concentrations in the atmosphere. In the field of sustainable packaging and materials, biotechnological applications offer innovative and climate-friendly solutions, just as they do in the field of sustainable textiles or in waste-to-value approaches in a circular economy.
Decline in turnover more moderate than expected
All-time high in expenditure for research & development
The biotech industry in Germany has achieved continuous growth in recent years. As expected, however, turnover in 2022 did not increase further. The subsiding of the pandemic and the resulting lower demand for the COVID-19 vaccine had already led to forecasts of a significant drop in sales. In fact, BioNTech suffered a €1.5 billion drop in sales. The industry’s turnover curve thus fell slightly (-4%) for the first time since 2013.
After exceeding the two billion mark for the first time in 2020, research and development (R&D) expenditure in biotechnology was able to break through the three billion mark in 2023. A total of €3.33 billion was invested in R&D, an increase of 17.6% compared to 2021. R&D spending by “red” biotech companies accounted for more than 90% of the industry’s total research expenditure.
Fig. 1: Turnover and R&D expenditure of dedicated biotech companies in EUR million 7.500 7.000
Turnover
6.500
R&D Expenditure
6.000 5.500 5.000 4.500 4.000 3.500 3.000
2,374
2.500
2,619 +10.5%
2,903 +10.9%
-1.4%
2,864
+5.9%
3,031
3,284 +8.3%
2.000 1,015
1.500 1.000 500
975
937
954
899
-3%
-4%
-4%
−3.7%
+6.2%
2010
2011
2012
2013
2014
+8.8%
0 2015
Name › BRAIN Biotech AG Address/P.O. Box › Darmstädter Str. 34–36 Postal Code/City › 64673 Zwingenberg State › Hesse Telephone › +49-6251-9331-0 Fax › +49-6251-9331-11 Email › public@brain-biotech.com Website › www.brain-biotech.com Social Media › I Number of Employees › ~ 330 (BRAIN Biotech Group; around 120 at headquarter in Zwingenberg, Germany) Founded (year) › 1993 Type of Laboratory › S1, S2, L1, L2 Areas of Activity › l Speciality Enzymes l Bioactive natural products / small molecules l Microbial strain development l Bioprocess Development l Biomanufacturing External › Collaborations with global players as Collaborations well as with renowned universities. Request for › We’re looking for partners in the food, Further Collaborations feed, chemicals and cosmetics industries to work with us to develop innovative bio-based solutions.
Creating a #BiobasedFuture BRAIN Biotech AG is a leading provider of biobased products and solutions for sustainable industrial processes. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group, which is active in these fields: › Research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural bioactive substances screening. › Production of speciality enzymes and proteins in industrial scale, with fermentation facilities in the UK and production facilities in continental Europe and the USA. › Bioincubator with own or partner-initiated R&D projects with high value-added potential. BRAIN Biotech’s focus areas are nutrition, health and the environment.
Technology services › Enzymes and Proteins: Function & sequence-driven discovery (proprietary database for rapid discovery) / Rational enzyme engineering / Bioinformatics · Designed and tailored for application › Microbial Strain Development – Microorganism discovery / Genetic & metabolic engineering /Production strains · Development of powerful protein & enzyme producers › Bioprocess Development: Process development & optimisation / Process transfer & scale-up / Analytics · Designed for production
BRAIN
R&D Services Genome Editing tools and services We use a proprietary CRISPR/Cas genome editing platform with a toolbox of several nucleases to perform custom genome editing services (“We CRISPR for you”) in a variety of applications. These genome editing tools have been identified and developed in-house, and are independent of common nucleases like e.g. Cas9 or Cas12a. We also provide and license these tools to our partners.
Enzymes optimization and search for new Enzymes If a particular enzyme product is not found in the BRAIN Biotech Group´s enzyme portfolio, our metagenome libraries are the basis for our sequence- or activitybased search for new enzyme product candidates. We further optimize enzymes already used by our customers so that complex process and application requirements can be met even better.
Process development and optimiziation We develop bioprocesses at lab-scale and to scale-up (200L) for process validation and sample generation. Our engineers within the BRAIN Biotech Group are experts for the tech and process transfer to enable a production at an industrial scale (up to 2 x 10,000L).
Applied technologies › Protein engineering › Eucaryotic cell expertise › Natural compound libraries › Genome editing / independent CRISPR nucleases › BRAIN BioArchive with access to nature‘s biodiversity › Metagenome technologies › Next generation sequencing › Precision fermentation & bio-processing › Applied bioinformatics › 3D modelling › Analytics
25 TH GUIDE TO GERMAN BIOTECH COMPANIES 2024
44 | 45